EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Regulatory implications of ctDNA in immuno-oncology for solid tumors

Paz J Vellanki, Soma Ghosh, Anand Pathak, Michael J Fusco, Erik W Bloomquist, Shenghui Tang, Harpreet Singh, Reena Philip, Richard Pazdur, Julia A Beaver

Journal for ImmunoTherapy of Cancer · 2023-02 · 11 (2) · e005344

DOI: 10.1136/jitc-2022-005344 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 16.02.2023. Verfasst von Paz J Vellanki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA Paz.Vellanki@fda.hhs.gov. Hauptthemen laut MEDLINE: Precision Medicine, Circulating Tumor DNA. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a minimally invasive approach for the diagnosis and management of patients with cancer and as an enrichment tool in clinical trials. In recent years, the US Food and Drug Administration has approved multiple ctDNA-based companion diagnostic assays for the safe and effective use of targeted therapies and ctDNA-based assays are also being developed for use with immuno-oncology-based therapies. For early-stage solid tumor cancers, ctDNA may be particularly important to detect molecular residual disease (MRD) to support early implementation of adjuvant or escalated therapy to prevent development of metastatic disease. Clinical trials are also increasingly using ctDNA MRD for patient selection and stratification, with an ultimate goal of improving trial efficiency through use of an enriched patient population. Standardization and harmonization of ctDNA assays and methodologies, along with further clinical validation of ctDNA as a prognostic and predictive biomarker, are necessary before ctDNA may be considered as an efficacy-response biomarker to support regulatory decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineCirculating Tumor DNAUnited StatesHumansMedical OncologyPrognosisNeoplasm, Residual

Stichwörter der Autor:innen

Clinical Trials as TopicImmunotherapyReview

Substanzen

Circulating Tumor DNA

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA Paz.Vellanki@fda.hhs.gov.
  • Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland, USA.

Zitieren

APA

Vellanki, P. J., Ghosh, S., Pathak, A., Fusco, M. J., Bloomquist, E. W., Tang, S., Singh, H., Philip, R., Pazdur, R., & Beaver, J. A. (2023). Regulatory implications of ctDNA in immuno-oncology for solid tumors. Journal for ImmunoTherapy of Cancer, 11(2), e005344. https://doi.org/10.1136/jitc-2022-005344

Vancouver

Vellanki PJ, Ghosh S, Pathak A, Fusco MJ, Bloomquist EW, Tang S, et al. Regulatory implications of ctDNA in immuno-oncology for solid tumors. Journal for ImmunoTherapy of Cancer. 2023;11(2):e005344. doi:10.1136/jitc-2022-005344

BibTeX
@article{Vellanki2023,
  author = {Vellanki, Paz J and Ghosh, Soma and Pathak, Anand and Fusco, Michael J and Bloomquist, Erik W and Tang, Shenghui and Singh, Harpreet and Philip, Reena and Pazdur, Richard and Beaver, Julia A},
  title = {Regulatory implications of ctDNA in immuno-oncology for solid tumors},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {2},
  pages = {e005344},
  doi = {10.1136/jitc-2022-005344}
}
Kostenlos starten →